DNTH (Dianthus Therapeutics) Ending Cash Position: $627.84 Mil (As of Mar. 2026)


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $98.07
GF Value $2.92
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Ending Cash Position?

Dianthus Therapeutics DNTH +2.41% 22 Ending Cash Position is $627.84 Mil as of Mar. 2026. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.92 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Dianthus Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $627.84 Mil.

Dianthus Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($56.15 Mil) to Dec. 2025 ($51.25 Mil) but then increased from Dec. 2025 ($51.25 Mil) to Mar. 2026 ($627.84 Mil).

Dianthus Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($132.39 Mil) to Dec. 2024 ($23.02 Mil) but then increased from Dec. 2024 ($23.02 Mil) to Dec. 2025 ($51.25 Mil).

Dianthus Therapeutics Ending Cash Position Related Terms

Dianthus Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Ending Cash Position Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
7.64 15.43 132.39 23.02 51.25

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.35 13.47 56.15 51.25 627.84
DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Dianthus Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.022+28.232
=51.25

Dianthus Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=51.254+576.581
=627.84

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $627.84 Mil mean?
Dianthus Therapeutics (DNTH) has a Ending Cash Position of $627.84 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Ending Cash Position too high?
Dianthus Therapeutics' current Ending Cash Position is $627.84 Mil. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Ending Cash Position compare to CAI and TNGX?
Dianthus Therapeutics' Ending Cash Position of $627.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Ending Cash Position is $627.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.92, compared to a current price of $98.07 — trading 3258.6% above its estimated fair value. The current Ending Cash Position is $627.84 Mil. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Ending Cash Position is $627.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $98.07 is trading 3258.6% above its estimated GF Value™ of $2.92. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Ending Cash Position: $627.84 Mil
  • GF Value™: $2.92 vs. price of $98.07 (3258.6% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$98.07
Price
$2.92
GF Value